Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans have higher sensitivity and specificity for detecting lymph nodes or metastatic disease relative to conventional imaging in prostate cancer staging. Since its FDA approval and incorporation into treatment guidelines,...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/24/6194 |
| _version_ | 1797461056961904640 |
|---|---|
| author | Ali Sabbagh Osama Mohamad Katie E. Lichter Thomas A. Hope |
| author_facet | Ali Sabbagh Osama Mohamad Katie E. Lichter Thomas A. Hope |
| author_sort | Ali Sabbagh |
| collection | DOAJ |
| description | Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans have higher sensitivity and specificity for detecting lymph nodes or metastatic disease relative to conventional imaging in prostate cancer staging. Since its FDA approval and incorporation into treatment guidelines, the use of PSMA PET has increased in patients undergoing initial staging, those with recurrence after initial definitive treatment, and patients with metastatic disease. Although the early detection of metastatic lesions is changing disease management, it is unclear whether this impact on management translates into clinical benefit. This review will summarize evidence pertaining to the change in patient management due to PSMA PET use and will discuss the implications of PSMA PET on treatment decisions in prostate cancer, particularly in the settings of biochemical recurrence and metachronous oligometastatic disease. |
| first_indexed | 2024-03-09T17:13:59Z |
| format | Article |
| id | doaj.art-0f241315c2de4f39aeb99741f1346926 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T17:13:59Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-0f241315c2de4f39aeb99741f13469262023-11-24T13:47:47ZengMDPI AGCancers2072-66942022-12-011424619410.3390/cancers14246194Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PETAli Sabbagh0Osama Mohamad1Katie E. Lichter2Thomas A. Hope3Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94158, USADepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA 94158, USADepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA 94158, USADepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USAProstate-specific membrane antigen (PSMA) positron emission tomography (PET) scans have higher sensitivity and specificity for detecting lymph nodes or metastatic disease relative to conventional imaging in prostate cancer staging. Since its FDA approval and incorporation into treatment guidelines, the use of PSMA PET has increased in patients undergoing initial staging, those with recurrence after initial definitive treatment, and patients with metastatic disease. Although the early detection of metastatic lesions is changing disease management, it is unclear whether this impact on management translates into clinical benefit. This review will summarize evidence pertaining to the change in patient management due to PSMA PET use and will discuss the implications of PSMA PET on treatment decisions in prostate cancer, particularly in the settings of biochemical recurrence and metachronous oligometastatic disease.https://www.mdpi.com/2072-6694/14/24/6194prostate cancerPET PSMAradiotherapyoligometastasisbiochemical recurrence |
| spellingShingle | Ali Sabbagh Osama Mohamad Katie E. Lichter Thomas A. Hope Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET Cancers prostate cancer PET PSMA radiotherapy oligometastasis biochemical recurrence |
| title | Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET |
| title_full | Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET |
| title_fullStr | Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET |
| title_full_unstemmed | Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET |
| title_short | Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET |
| title_sort | management of patients with recurrent and metachronous oligometastatic prostate cancer in the era of psma pet |
| topic | prostate cancer PET PSMA radiotherapy oligometastasis biochemical recurrence |
| url | https://www.mdpi.com/2072-6694/14/24/6194 |
| work_keys_str_mv | AT alisabbagh managementofpatientswithrecurrentandmetachronousoligometastaticprostatecancerintheeraofpsmapet AT osamamohamad managementofpatientswithrecurrentandmetachronousoligometastaticprostatecancerintheeraofpsmapet AT katieelichter managementofpatientswithrecurrentandmetachronousoligometastaticprostatecancerintheeraofpsmapet AT thomasahope managementofpatientswithrecurrentandmetachronousoligometastaticprostatecancerintheeraofpsmapet |